Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug candidates, and will initiate proof of concept preclinical studies to further measure the viability of these compounds as daily pro-cognitive take-home medication.
The company said that its Family 3 of next-generation psilocybin compounds have demonstrated low levels of activity at the 5-HT2A receptor and long half-lives.
“Our scientists designed and developed a unique class of novel and patentable compounds, our ‘Family 3,’ which have shown promise as a substitute for microdosing approaches due to their low activity at the 5-HT2A receptor,” said James Lanthier, CEO of Mindset. “This validates our decision to study the efficacy of these compounds further for pro-cognitive indications associated with neurological and mental health disorders.”
He added: “If we can demonstrate pro-cognitive benefits at a range of sub-hallucinogenic doses, our compounds have the potential to dramatically broaden the addressable neurology and mental health market we are pursuing while avoiding the hallucinogenic liability associated with traditional approaches.”
READ: Mindset Pharma enters manufacturing deal with leading CDMO for next-generation psilocybin drug candidate, MSP-1014
Lanthier noted that providing pro-cognitive solutions that do not elicit a psychedelic effect will suit vulnerable patient populations such as juvenile ADHD, Alzheimer's disease, and a range of others.
To better understand potential pro-cognitive benefits across a range of sub-hallucinogenic doses, Mindset will initiate a series of in vivo proof of concept studies, which will measure motivation and attention. These studies will be critical in establishing the clinical viability of its Family 3 drug candidates, the company said.
Mindset recently announced a first-of-its-kind co-development agreement with the McQuade Center of Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, which fully funds and advances the development of Mindset’s Family 2 & Family 4.
Family 3 compounds are potential opportunities for Mindset to partner with other groups to progress its most promising candidates from this family to the clinic.
Contact Ritika at ritika@proactiveinvestors.com